Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 260

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 260
---
 we completed the Pre -INDdiscussions with the US FDA on ALS -4. In March 2023, we also announced the completion of the End of Phase 1 (EOP1) meeting of SACT -1with the US FDA. The FDA generally agreed with the chemistry -manufacturing -control(CMC) strategy and our proposed clinical development plan for SACT -1Phase 1/2 trials. Currently, ALS -4and SACT -1are Phase 2 clinical trials ready. During the second quarter of 2023, the Company made a decision to streamline its operations by terminating clinic services and suspending work on non -leadproducts. This measure is aimed at optimizing the allocation of our resources and focusing our efforts on advancing our lead projects, which hold the most promise for commercial success and beneficial impact. This decision aligns with our commitment to enhance shareholder value and effectively drive our core objectives forward in the competitive landscape. 143 Proposed Merger and Subsequent Termination of Merger Agreement On March 1, 2024, we entered into an Agreement and Plan of Merger with YOOV Group Holding Limited, a company organized under the laws of British Virgin Islands (“YOOV”), pursuant to which YOOV was to become one of our wholly owned subsidiaries. However, on October 25, 2024, the parties to the Agreement and Plan of Merger entered into a termination agreement (the “Termination Agreement”), pursuant to which the parties agreed to terminate the Agreement and Plan of Merger on the date thereof, and such agreement became null and void and of no further force or effect. Registered Direct Offering On January 2, 2025, the Company entered into a certain securities purchase agreement (the “Securities Purchase Agreement”) with certain non -affiliatedinstitutional investors pursuant to which the Company sold 1,535,000 Class A ordinary shares of the Company at a per share price of $2.00 in a registered direct offering, for gross proceeds of $3,070,000 (the “RDO”). Private Placement Offerings Sales of convertible notes On September 11, 2023, the Company entered into a Securities Purchase Agreement with Jurchen Investment Corporation, the largest shareholder of the Company, pursuant to which the Company sold a secured convertible note in the aggregate principal amount of $3,000,000 (the “Sep 2023 Notes”). The Sep 2023 Notes are convertible into the Company’s Class A ordinary shares and have a maturity date that